Pharming Group N.V.

Total Valuation

Pharming Group N.V. carries a market capitalization of 864.45M, placing it among publicly traded companies globally. Its enterprise value stands at 959.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Pharming Group N.V. currently has 706.25M shares outstanding.

Valuation Ratios

Pharming Group N.V. trades at a trailing price-to-earnings ratio of 82.20. The price-to-sales ratio is 2.74, and the price-to-book ratio stands at -3.71.

Enterprise Valuation

On an enterprise value basis, Pharming Group N.V. trades at an EV/EBITDA multiple of 28.89 and an EV/FCF ratio of 15.04. The EV/Sales ratio of 2.60 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 44.70 provides insight into valuation relative to core operating earnings.

Financial Position

Pharming Group N.V. maintains a current ratio of 2.63, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.21, indicating elevated leverage, while an interest coverage ratio of 2.76 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Pharming Group N.V. has paid 7.70M in income taxes, reflecting an effective tax rate of 38.71.

Stock Price Statistics

Pharming Group N.V.'s stock has gained approximately 8.99377% over the past 52 weeks. The 50-day moving average sits at 15.35, while the 200-day moving average is 15.73.

Income Statement

Over the trailing twelve months, Pharming Group N.V. generated 369.46M in revenue and converted that into 12.33M in net income, yielding earnings per share of 0.16. EBITDA reached 33.21M, while operating income came in at 21.46M.

Balance Sheet

Pharming Group N.V. holds 170.18M in cash and equivalents against 116.21M in total debt, resulting in a net debt position of 46.39M. Total book value stands at -273.39M, with working capital of 183.17M providing operational flexibility.

Cash Flow

Pharming Group N.V. produced 56.43M in operating cash flow over the past twelve months.

Margins

Pharming Group N.V. operates with a gross margin of 88.15, reflecting its pricing power and cost economics. The operating margin of 5.81 and net profit margin of 3.34 provide insight into operational efficiency.

Dividends & Yields

Scores

Pharming Group N.V. posts an Altman Z-Score of 3.50, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.